The Experts below are selected from a list of 246 Experts worldwide ranked by ideXlab platform
Pamela Maffioli - One of the best experts on this subject based on the ideXlab platform.
-
retracted Enalapril lercanidipine combination on markers of cardiovascular risk a randomized study
Journal of The American Society of Hypertension, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela Dangelo, Pamela MaffioliAbstract:: The aim of this study was to evaluate Enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to Enalapril 20 mg, lercanidipine 10 mg, or Enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-α (TNF-α). We recorded a decrease of BP in all groups, with the Enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline, with Enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if Enalapril/lercanidipine combination was more effective than single monotherapies. TNF-α and Hs-CRP were greater reduced by Enalapril/lercanidipine combination compared with Enalapril (P < .05 for both). The Enalapril/lercanidipine fixed combination was more effective than single monotherapies in decreasing BP, but also in improving markers of cardiovascular risk stratification in hypertensive patients.
-
effects of Enalapril lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients
Journal of Clinical Pharmacy and Therapeutics, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela Dangelo, Pamela MaffioliAbstract:Summary What is known and objective There is considerable interest in pharmacogenetic and molecular biomarkers. Our aim was to evaluate the effects of Enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients, such as lipoprotein(a) [Lp(a)], soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L) and serum myeloperoxidase (MPO). Research design and methods Three hundred and forty-five patients were enrolled in this randomized, double-blind, clinical trial: 120 hypertensive patients were randomized to Enalapril 20 mg, 110 to lercanidipine 10 mg and 115 to Enalapril/lercanidipine 20/10 mg fixed combination. We measures the following markers at baseline and after 6, 12, 18 and 24 months: blood pressure, fasting plasma glucose (FPG), lipid profile, Lp(a), sRAGE, sCD40L and MPO. Results There was a decrease in blood pressure in all groups compared with baseline, even if, as expected, Enalapril/lercanidipine combination was more effective in reducing blood pressure compared with the monotherapies. No variations in lipid profile or FPG were recorded in any of the groups. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline. The combination Enalapril/lercanidipine improved it more than the single therapies. All treatments increased sRAGE levels, and decreased sCD40L and MPO, with a better effect seen with the Enalapril/lercanidipine combination compared with single monotherapies. What is new and conclusion The combination Enalapril/lercanidipine seems to be better than the single monotherapies in reducing not only blood pressure, but also the levels of some emerging biomarkers, potentially useful for cardiovascular risk stratification of hypertensive patients.
-
RETRACTED: Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study
Journal of The American Society of Hypertension, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela D'angelo, Pamela MaffioliAbstract:: The aim of this study was to evaluate Enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to Enalapril 20 mg, lercanidipine 10 mg, or Enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-α (TNF-α). We recorded a decrease of BP in all groups, with the Enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline, with Enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if Enalapril/lercanidipine combination was more effective than single monotherapies. TNF-α and Hs-CRP were greater reduced by Enalapril/lercanidipine combination compared with Enalapril (P < .05 for both). The Enalapril/lercanidipine fixed combination was more effective than single monotherapies in decreasing BP, but also in improving markers of cardiovascular risk stratification in hypertensive patients.
-
Effects of Enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients.
Journal of Clinical Pharmacy and Therapeutics, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela D'angelo, Pamela MaffioliAbstract:Summary What is known and objective There is considerable interest in pharmacogenetic and molecular biomarkers. Our aim was to evaluate the effects of Enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients, such as lipoprotein(a) [Lp(a)], soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L) and serum myeloperoxidase (MPO). Research design and methods Three hundred and forty-five patients were enrolled in this randomized, double-blind, clinical trial: 120 hypertensive patients were randomized to Enalapril 20 mg, 110 to lercanidipine 10 mg and 115 to Enalapril/lercanidipine 20/10 mg fixed combination. We measures the following markers at baseline and after 6, 12, 18 and 24 months: blood pressure, fasting plasma glucose (FPG), lipid profile, Lp(a), sRAGE, sCD40L and MPO. Results There was a decrease in blood pressure in all groups compared with baseline, even if, as expected, Enalapril/lercanidipine combination was more effective in reducing blood pressure compared with the monotherapies. No variations in lipid profile or FPG were recorded in any of the groups. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline. The combination Enalapril/lercanidipine improved it more than the single therapies. All treatments increased sRAGE levels, and decreased sCD40L and MPO, with a better effect seen with the Enalapril/lercanidipine combination compared with single monotherapies. What is new and conclusion The combination Enalapril/lercanidipine seems to be better than the single monotherapies in reducing not only blood pressure, but also the levels of some emerging biomarkers, potentially useful for cardiovascular risk stratification of hypertensive patients.
Giuseppe Derosa - One of the best experts on this subject based on the ideXlab platform.
-
retracted Enalapril lercanidipine combination on markers of cardiovascular risk a randomized study
Journal of The American Society of Hypertension, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela Dangelo, Pamela MaffioliAbstract:: The aim of this study was to evaluate Enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to Enalapril 20 mg, lercanidipine 10 mg, or Enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-α (TNF-α). We recorded a decrease of BP in all groups, with the Enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline, with Enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if Enalapril/lercanidipine combination was more effective than single monotherapies. TNF-α and Hs-CRP were greater reduced by Enalapril/lercanidipine combination compared with Enalapril (P < .05 for both). The Enalapril/lercanidipine fixed combination was more effective than single monotherapies in decreasing BP, but also in improving markers of cardiovascular risk stratification in hypertensive patients.
-
effects of Enalapril lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients
Journal of Clinical Pharmacy and Therapeutics, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela Dangelo, Pamela MaffioliAbstract:Summary What is known and objective There is considerable interest in pharmacogenetic and molecular biomarkers. Our aim was to evaluate the effects of Enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients, such as lipoprotein(a) [Lp(a)], soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L) and serum myeloperoxidase (MPO). Research design and methods Three hundred and forty-five patients were enrolled in this randomized, double-blind, clinical trial: 120 hypertensive patients were randomized to Enalapril 20 mg, 110 to lercanidipine 10 mg and 115 to Enalapril/lercanidipine 20/10 mg fixed combination. We measures the following markers at baseline and after 6, 12, 18 and 24 months: blood pressure, fasting plasma glucose (FPG), lipid profile, Lp(a), sRAGE, sCD40L and MPO. Results There was a decrease in blood pressure in all groups compared with baseline, even if, as expected, Enalapril/lercanidipine combination was more effective in reducing blood pressure compared with the monotherapies. No variations in lipid profile or FPG were recorded in any of the groups. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline. The combination Enalapril/lercanidipine improved it more than the single therapies. All treatments increased sRAGE levels, and decreased sCD40L and MPO, with a better effect seen with the Enalapril/lercanidipine combination compared with single monotherapies. What is new and conclusion The combination Enalapril/lercanidipine seems to be better than the single monotherapies in reducing not only blood pressure, but also the levels of some emerging biomarkers, potentially useful for cardiovascular risk stratification of hypertensive patients.
-
RETRACTED: Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study
Journal of The American Society of Hypertension, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela D'angelo, Pamela MaffioliAbstract:: The aim of this study was to evaluate Enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to Enalapril 20 mg, lercanidipine 10 mg, or Enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-α (TNF-α). We recorded a decrease of BP in all groups, with the Enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline, with Enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if Enalapril/lercanidipine combination was more effective than single monotherapies. TNF-α and Hs-CRP were greater reduced by Enalapril/lercanidipine combination compared with Enalapril (P < .05 for both). The Enalapril/lercanidipine fixed combination was more effective than single monotherapies in decreasing BP, but also in improving markers of cardiovascular risk stratification in hypertensive patients.
-
Effects of Enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients.
Journal of Clinical Pharmacy and Therapeutics, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela D'angelo, Pamela MaffioliAbstract:Summary What is known and objective There is considerable interest in pharmacogenetic and molecular biomarkers. Our aim was to evaluate the effects of Enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients, such as lipoprotein(a) [Lp(a)], soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L) and serum myeloperoxidase (MPO). Research design and methods Three hundred and forty-five patients were enrolled in this randomized, double-blind, clinical trial: 120 hypertensive patients were randomized to Enalapril 20 mg, 110 to lercanidipine 10 mg and 115 to Enalapril/lercanidipine 20/10 mg fixed combination. We measures the following markers at baseline and after 6, 12, 18 and 24 months: blood pressure, fasting plasma glucose (FPG), lipid profile, Lp(a), sRAGE, sCD40L and MPO. Results There was a decrease in blood pressure in all groups compared with baseline, even if, as expected, Enalapril/lercanidipine combination was more effective in reducing blood pressure compared with the monotherapies. No variations in lipid profile or FPG were recorded in any of the groups. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline. The combination Enalapril/lercanidipine improved it more than the single therapies. All treatments increased sRAGE levels, and decreased sCD40L and MPO, with a better effect seen with the Enalapril/lercanidipine combination compared with single monotherapies. What is new and conclusion The combination Enalapril/lercanidipine seems to be better than the single monotherapies in reducing not only blood pressure, but also the levels of some emerging biomarkers, potentially useful for cardiovascular risk stratification of hypertensive patients.
Lucio Bianchi - One of the best experts on this subject based on the ideXlab platform.
-
retracted Enalapril lercanidipine combination on markers of cardiovascular risk a randomized study
Journal of The American Society of Hypertension, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela Dangelo, Pamela MaffioliAbstract:: The aim of this study was to evaluate Enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to Enalapril 20 mg, lercanidipine 10 mg, or Enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-α (TNF-α). We recorded a decrease of BP in all groups, with the Enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline, with Enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if Enalapril/lercanidipine combination was more effective than single monotherapies. TNF-α and Hs-CRP were greater reduced by Enalapril/lercanidipine combination compared with Enalapril (P < .05 for both). The Enalapril/lercanidipine fixed combination was more effective than single monotherapies in decreasing BP, but also in improving markers of cardiovascular risk stratification in hypertensive patients.
-
effects of Enalapril lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients
Journal of Clinical Pharmacy and Therapeutics, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela Dangelo, Pamela MaffioliAbstract:Summary What is known and objective There is considerable interest in pharmacogenetic and molecular biomarkers. Our aim was to evaluate the effects of Enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients, such as lipoprotein(a) [Lp(a)], soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L) and serum myeloperoxidase (MPO). Research design and methods Three hundred and forty-five patients were enrolled in this randomized, double-blind, clinical trial: 120 hypertensive patients were randomized to Enalapril 20 mg, 110 to lercanidipine 10 mg and 115 to Enalapril/lercanidipine 20/10 mg fixed combination. We measures the following markers at baseline and after 6, 12, 18 and 24 months: blood pressure, fasting plasma glucose (FPG), lipid profile, Lp(a), sRAGE, sCD40L and MPO. Results There was a decrease in blood pressure in all groups compared with baseline, even if, as expected, Enalapril/lercanidipine combination was more effective in reducing blood pressure compared with the monotherapies. No variations in lipid profile or FPG were recorded in any of the groups. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline. The combination Enalapril/lercanidipine improved it more than the single therapies. All treatments increased sRAGE levels, and decreased sCD40L and MPO, with a better effect seen with the Enalapril/lercanidipine combination compared with single monotherapies. What is new and conclusion The combination Enalapril/lercanidipine seems to be better than the single monotherapies in reducing not only blood pressure, but also the levels of some emerging biomarkers, potentially useful for cardiovascular risk stratification of hypertensive patients.
-
RETRACTED: Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study
Journal of The American Society of Hypertension, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela D'angelo, Pamela MaffioliAbstract:: The aim of this study was to evaluate Enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to Enalapril 20 mg, lercanidipine 10 mg, or Enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-α (TNF-α). We recorded a decrease of BP in all groups, with the Enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline, with Enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if Enalapril/lercanidipine combination was more effective than single monotherapies. TNF-α and Hs-CRP were greater reduced by Enalapril/lercanidipine combination compared with Enalapril (P < .05 for both). The Enalapril/lercanidipine fixed combination was more effective than single monotherapies in decreasing BP, but also in improving markers of cardiovascular risk stratification in hypertensive patients.
-
Effects of Enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients.
Journal of Clinical Pharmacy and Therapeutics, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela D'angelo, Pamela MaffioliAbstract:Summary What is known and objective There is considerable interest in pharmacogenetic and molecular biomarkers. Our aim was to evaluate the effects of Enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients, such as lipoprotein(a) [Lp(a)], soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L) and serum myeloperoxidase (MPO). Research design and methods Three hundred and forty-five patients were enrolled in this randomized, double-blind, clinical trial: 120 hypertensive patients were randomized to Enalapril 20 mg, 110 to lercanidipine 10 mg and 115 to Enalapril/lercanidipine 20/10 mg fixed combination. We measures the following markers at baseline and after 6, 12, 18 and 24 months: blood pressure, fasting plasma glucose (FPG), lipid profile, Lp(a), sRAGE, sCD40L and MPO. Results There was a decrease in blood pressure in all groups compared with baseline, even if, as expected, Enalapril/lercanidipine combination was more effective in reducing blood pressure compared with the monotherapies. No variations in lipid profile or FPG were recorded in any of the groups. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline. The combination Enalapril/lercanidipine improved it more than the single therapies. All treatments increased sRAGE levels, and decreased sCD40L and MPO, with a better effect seen with the Enalapril/lercanidipine combination compared with single monotherapies. What is new and conclusion The combination Enalapril/lercanidipine seems to be better than the single monotherapies in reducing not only blood pressure, but also the levels of some emerging biomarkers, potentially useful for cardiovascular risk stratification of hypertensive patients.
Davide Romano - One of the best experts on this subject based on the ideXlab platform.
-
retracted Enalapril lercanidipine combination on markers of cardiovascular risk a randomized study
Journal of The American Society of Hypertension, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela Dangelo, Pamela MaffioliAbstract:: The aim of this study was to evaluate Enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to Enalapril 20 mg, lercanidipine 10 mg, or Enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-α (TNF-α). We recorded a decrease of BP in all groups, with the Enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline, with Enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if Enalapril/lercanidipine combination was more effective than single monotherapies. TNF-α and Hs-CRP were greater reduced by Enalapril/lercanidipine combination compared with Enalapril (P < .05 for both). The Enalapril/lercanidipine fixed combination was more effective than single monotherapies in decreasing BP, but also in improving markers of cardiovascular risk stratification in hypertensive patients.
-
effects of Enalapril lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients
Journal of Clinical Pharmacy and Therapeutics, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela Dangelo, Pamela MaffioliAbstract:Summary What is known and objective There is considerable interest in pharmacogenetic and molecular biomarkers. Our aim was to evaluate the effects of Enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients, such as lipoprotein(a) [Lp(a)], soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L) and serum myeloperoxidase (MPO). Research design and methods Three hundred and forty-five patients were enrolled in this randomized, double-blind, clinical trial: 120 hypertensive patients were randomized to Enalapril 20 mg, 110 to lercanidipine 10 mg and 115 to Enalapril/lercanidipine 20/10 mg fixed combination. We measures the following markers at baseline and after 6, 12, 18 and 24 months: blood pressure, fasting plasma glucose (FPG), lipid profile, Lp(a), sRAGE, sCD40L and MPO. Results There was a decrease in blood pressure in all groups compared with baseline, even if, as expected, Enalapril/lercanidipine combination was more effective in reducing blood pressure compared with the monotherapies. No variations in lipid profile or FPG were recorded in any of the groups. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline. The combination Enalapril/lercanidipine improved it more than the single therapies. All treatments increased sRAGE levels, and decreased sCD40L and MPO, with a better effect seen with the Enalapril/lercanidipine combination compared with single monotherapies. What is new and conclusion The combination Enalapril/lercanidipine seems to be better than the single monotherapies in reducing not only blood pressure, but also the levels of some emerging biomarkers, potentially useful for cardiovascular risk stratification of hypertensive patients.
-
RETRACTED: Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study
Journal of The American Society of Hypertension, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela D'angelo, Pamela MaffioliAbstract:: The aim of this study was to evaluate Enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to Enalapril 20 mg, lercanidipine 10 mg, or Enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-α (TNF-α). We recorded a decrease of BP in all groups, with the Enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline, with Enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if Enalapril/lercanidipine combination was more effective than single monotherapies. TNF-α and Hs-CRP were greater reduced by Enalapril/lercanidipine combination compared with Enalapril (P < .05 for both). The Enalapril/lercanidipine fixed combination was more effective than single monotherapies in decreasing BP, but also in improving markers of cardiovascular risk stratification in hypertensive patients.
-
Effects of Enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients.
Journal of Clinical Pharmacy and Therapeutics, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela D'angelo, Pamela MaffioliAbstract:Summary What is known and objective There is considerable interest in pharmacogenetic and molecular biomarkers. Our aim was to evaluate the effects of Enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients, such as lipoprotein(a) [Lp(a)], soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L) and serum myeloperoxidase (MPO). Research design and methods Three hundred and forty-five patients were enrolled in this randomized, double-blind, clinical trial: 120 hypertensive patients were randomized to Enalapril 20 mg, 110 to lercanidipine 10 mg and 115 to Enalapril/lercanidipine 20/10 mg fixed combination. We measures the following markers at baseline and after 6, 12, 18 and 24 months: blood pressure, fasting plasma glucose (FPG), lipid profile, Lp(a), sRAGE, sCD40L and MPO. Results There was a decrease in blood pressure in all groups compared with baseline, even if, as expected, Enalapril/lercanidipine combination was more effective in reducing blood pressure compared with the monotherapies. No variations in lipid profile or FPG were recorded in any of the groups. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline. The combination Enalapril/lercanidipine improved it more than the single therapies. All treatments increased sRAGE levels, and decreased sCD40L and MPO, with a better effect seen with the Enalapril/lercanidipine combination compared with single monotherapies. What is new and conclusion The combination Enalapril/lercanidipine seems to be better than the single monotherapies in reducing not only blood pressure, but also the levels of some emerging biomarkers, potentially useful for cardiovascular risk stratification of hypertensive patients.
Elena Fogari - One of the best experts on this subject based on the ideXlab platform.
-
retracted Enalapril lercanidipine combination on markers of cardiovascular risk a randomized study
Journal of The American Society of Hypertension, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela Dangelo, Pamela MaffioliAbstract:: The aim of this study was to evaluate Enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to Enalapril 20 mg, lercanidipine 10 mg, or Enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-α (TNF-α). We recorded a decrease of BP in all groups, with the Enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline, with Enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if Enalapril/lercanidipine combination was more effective than single monotherapies. TNF-α and Hs-CRP were greater reduced by Enalapril/lercanidipine combination compared with Enalapril (P < .05 for both). The Enalapril/lercanidipine fixed combination was more effective than single monotherapies in decreasing BP, but also in improving markers of cardiovascular risk stratification in hypertensive patients.
-
effects of Enalapril lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients
Journal of Clinical Pharmacy and Therapeutics, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela Dangelo, Pamela MaffioliAbstract:Summary What is known and objective There is considerable interest in pharmacogenetic and molecular biomarkers. Our aim was to evaluate the effects of Enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients, such as lipoprotein(a) [Lp(a)], soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L) and serum myeloperoxidase (MPO). Research design and methods Three hundred and forty-five patients were enrolled in this randomized, double-blind, clinical trial: 120 hypertensive patients were randomized to Enalapril 20 mg, 110 to lercanidipine 10 mg and 115 to Enalapril/lercanidipine 20/10 mg fixed combination. We measures the following markers at baseline and after 6, 12, 18 and 24 months: blood pressure, fasting plasma glucose (FPG), lipid profile, Lp(a), sRAGE, sCD40L and MPO. Results There was a decrease in blood pressure in all groups compared with baseline, even if, as expected, Enalapril/lercanidipine combination was more effective in reducing blood pressure compared with the monotherapies. No variations in lipid profile or FPG were recorded in any of the groups. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline. The combination Enalapril/lercanidipine improved it more than the single therapies. All treatments increased sRAGE levels, and decreased sCD40L and MPO, with a better effect seen with the Enalapril/lercanidipine combination compared with single monotherapies. What is new and conclusion The combination Enalapril/lercanidipine seems to be better than the single monotherapies in reducing not only blood pressure, but also the levels of some emerging biomarkers, potentially useful for cardiovascular risk stratification of hypertensive patients.
-
RETRACTED: Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study
Journal of The American Society of Hypertension, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela D'angelo, Pamela MaffioliAbstract:: The aim of this study was to evaluate Enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to Enalapril 20 mg, lercanidipine 10 mg, or Enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-α (TNF-α). We recorded a decrease of BP in all groups, with the Enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline, with Enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if Enalapril/lercanidipine combination was more effective than single monotherapies. TNF-α and Hs-CRP were greater reduced by Enalapril/lercanidipine combination compared with Enalapril (P < .05 for both). The Enalapril/lercanidipine fixed combination was more effective than single monotherapies in decreasing BP, but also in improving markers of cardiovascular risk stratification in hypertensive patients.
-
Effects of Enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients.
Journal of Clinical Pharmacy and Therapeutics, 2014Co-Authors: Giuseppe Derosa, Elena Fogari, Lucio Bianchi, Davide Romano, Aldo Bonaventura, Angela D'angelo, Pamela MaffioliAbstract:Summary What is known and objective There is considerable interest in pharmacogenetic and molecular biomarkers. Our aim was to evaluate the effects of Enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients, such as lipoprotein(a) [Lp(a)], soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L) and serum myeloperoxidase (MPO). Research design and methods Three hundred and forty-five patients were enrolled in this randomized, double-blind, clinical trial: 120 hypertensive patients were randomized to Enalapril 20 mg, 110 to lercanidipine 10 mg and 115 to Enalapril/lercanidipine 20/10 mg fixed combination. We measures the following markers at baseline and after 6, 12, 18 and 24 months: blood pressure, fasting plasma glucose (FPG), lipid profile, Lp(a), sRAGE, sCD40L and MPO. Results There was a decrease in blood pressure in all groups compared with baseline, even if, as expected, Enalapril/lercanidipine combination was more effective in reducing blood pressure compared with the monotherapies. No variations in lipid profile or FPG were recorded in any of the groups. Lercanidipine, but not Enalapril, improved Lp(a) levels compared with baseline. The combination Enalapril/lercanidipine improved it more than the single therapies. All treatments increased sRAGE levels, and decreased sCD40L and MPO, with a better effect seen with the Enalapril/lercanidipine combination compared with single monotherapies. What is new and conclusion The combination Enalapril/lercanidipine seems to be better than the single monotherapies in reducing not only blood pressure, but also the levels of some emerging biomarkers, potentially useful for cardiovascular risk stratification of hypertensive patients.